Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Techne, Regulus Therapeutics to Develop Assays for Kidney Disease Treatment

NEW YORK ─ Bio-Techne and Regulus Therapeutics on Wednesday announced a collaboration to support biomarker assay development and biomarker analysis for the clinical development of Regulus' RGLS4326, an autosomal dominant polycystic kidney disease (ADPKD) treatment.

Regulus has used two Bio-Techne branded product lines, ProteinSimple and Exosome Diagnostics, to help with its clinical trial patient testing, Bio-Techne said. 

Minneapolis-based Bio-Techne added that the collaboration involves developing biomarker assays to support the assessment of levels of polycystin 1 (PC1) and polycystin 2 (PC2) using its fully automated Simple Western instrument to read out results. Its Exosome Diagnostics business ─ with clinical laboratories in Waltham, Massachusetts, and Munich ─ isolates and analyzes exosomes to measure RNA, cell-free DNA, and proteins to explore and identify biomarkers, Bio-Techne said. 

Patients with ADPKD have been reported to have low levels of PC1 and PC2, the proteins encoded by the PKD1 and PKD2 genes, due to a mutation in polycystic kidney disease genes.

RGLS4326 is a first-in-class anti-miR-17 therapy in Phase 1b clinical development in ADPKD patients. The Phase 1b trial is an adaptive design, open-label, multiple-dose study in up to three cohorts of patients with ADPKD.

Investigators expect to enroll up to nine patients in a first patient cohort who will receive RGLS4326 every two weeks over six weeks, and they anticipate that results for the cohort will be available by the end of Q1 2021.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.